Novo Nordisk A/s

Helle Heibroch Petersen

Ida Hilden

Lars Christian Petersen

Berit Olsen Krogh

Jens Breinholt

Jes Thorn Clausen

Mikael Kofod-Hansen

Brit Binow Soerensen

Anders Svensson

Cecilia Augustsson

Brit Binow Sørensen

The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.

Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)

The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI&#x3b1;, even where the concentration of TFPI is abnormally elevated.

Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.

Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity

The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

Antibodies that are capable of specifically binding tissue factor pathway inhibitor

The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

Growing community of inventors

Koebenhavn V, Denmark

Helle Heibroch Petersen